Abstract
The overall aim of this book is to set out the main changes needed in the field of economic and regulatory conditions as a consequence of these rapid developments in oncology. The traditional approaches of health economics, like health economic evaluation, health technology assessment (HTA), modeling methods, assessing value, pricing techniques, are bound to be altered in the contributions to this book. It is understandable that with the life-threatening diagnosis of cancer the new treatment options need to be accompanied by the best available health economic tools. This pertains to well-implemented decision rules concerning willingness to pay, incremental cost-effectiveness ratio thresholds, equity, patient access, end of life criteria, etc. Their application differs with regard to the usual health economic analyzes implemented in other treatment areas. Overstating a bit one could ask whether we need a strongly modified concept of oncology economics?
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
IQVIA Institute (2018). https://www.iqvia.com/institute/reports/global-oncology-trends-2018. Accessed 15 June 2018
Kleinrock M (2015) Oncology innovation and challenging choices: balancing value and funding priorities in light of an abundance of new treatment options. Am Health Drug Benefits 8(4):196–199
McKinsey & Company (2016). https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/The%20next%20wave%20of%20innovation%20in%20oncology/The-next-wave-of-innovation-in-oncology.ashx. Accessed 15 Mar 2018
Miller JD, Foley KA, Russell MW (2014) Current challenges in health economic modeling of cancer therapies: a research inquiry. Am Health Drug Benefits 7(3):153–162
Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, MartÃnez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A (2017) Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open (2018 Feb) 2;3(2):e000285. https://doi.org/10.1136/esmoopen-2017-000285 (eCollection 2018)
Reuters (2017). https://www.reuters.com/article/us-health-cancer-drug-prices/cancer-drug-prices-rising-far-faster-than-inflation-idUSKBN1CN2852017. Accessed 15 Mar 2018
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Walter, E. (2019). Introduction and Overview. In: Walter, E. (eds) Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research, vol 213. Springer, Cham. https://doi.org/10.1007/978-3-030-01207-6_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-01207-6_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01206-9
Online ISBN: 978-3-030-01207-6
eBook Packages: MedicineMedicine (R0)